Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results

Phase III Data Could Lead To First Approval

 
• By Alaric DeArment
  
Vitiligo on the hands. Shutterstock 1621981522
Incyte reported positive Phase III topline results for topical ruxolitinib in vitiligo • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

More from Therapeutic Category